-
Somaxon Pharmaceuticals Rumor on Patents (SOMX)
Wednesday, March 30, 2011 - 11:10am | 68Rumors circulating from speculative sources that Somaxon Pharma (NASDAQ: SOMX) has had some patents approved. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your...
-
Options Brief: Endo Pharmaceuticals Holdings (ENDP)
Wednesday, March 30, 2011 - 10:52am | 99Shares of Endo Pharmaceuticals Holdings (NASDAQ: ENDP) are higher on the session by 4.23%, trading at $36.20. Overall call volume is now running at 3.65x the daily average, with 52% of all calls traded being purchases on the offer. 1,587 contracts have traded on the session so far. Endo...
-
Top Narrow Based Indexes For March 30 (CEPH, VRX)
Wednesday, March 30, 2011 - 10:35am | 230By 10:33 am, the Dow Jones Industrial Average was up 61.19 points, or 0.50%, to 12,340.20, while the broader Standard & Poor's 500 index had gained 5.99 points, or 0.45%. The NASDAQ composite index rose 11.00 points, or 0.40%. Some of the narrow based indexes that are driving the markets are...
-
Benzinga's Volume Movers (CEPH, SHPGY, CLNE, WPRT)
Wednesday, March 30, 2011 - 10:26am | 173Cephalon Inc (NASDAQ: CEPH) shares moved up 28.02% to $75.21 at 10:25 am. The volume of CEPH shares traded was 4404% higher than normal. Valeant Pharmaceuticals International (NYSE: VRX) made an unsolicited $5.7 billion offer to purchase Cephalon. Shire plc (NASDAQ: SHPGY) shares rose 1.01% to $87...
-
Stock breaking out new High (PTIE) $9.11
Wednesday, March 30, 2011 - 9:56am | 13Stock breaking out new High (PTIE) $9.11...
-
Morning Market Movers (CEPH, NLST, BVX, OXM)
Wednesday, March 30, 2011 - 9:49am | 139Cephalon Inc (NASDAQ: CEPH) shares surged 28.34% to $75.40 at 9:45 am. Valeant Pharmaceuticals International (NYSE: VRX) made an unsolicited $5.7 billion offer to purchase Cephalon. Netlist Inc (NASDAQ: NLST) shares advanced 23.55% to $2.99. NLST received 3 patents related to hypercloud memory...
-
Cephalon Trading Higher Than $73 Buyout Offer; Bidder CEO Says "Will Move On" If Cephalon Desires Independence (CEPH, VRX)
Wednesday, March 30, 2011 - 9:42am | 327Cephalon (NASDAQ: CEPH) is currently trading significantly higher than the $73 aggressive buyout offer made yesterday by Valeant Pharma (NYSE: VRX). At last check, Cephalon was trading at $75.34, a 3% premium above the buyout price. Increasing the urgency of the bid, Valeant's CEO recently...
-
Valeant CEO Says Will Move On If Cephalon Stakeholders Prefer Independence (CEPH, VRX)
Wednesday, March 30, 2011 - 9:33am | 36Regarding The Recent Buyout Offer, Valeant (NYSE: VRX) CEO Says Will Move On If Cephalon (NASDAQ: CEPH) Stakeholders Prefer Independence.
-
Pre-market News And Views
Wednesday, March 30, 2011 - 9:29am | 386What can we say? The S&P 500 Index futures (ES M1) are trading higher again this morning by 6.00 points to 1322.50 per contract. The S&P 500 futures have now rallied higher by 81.0 points in just 10 trading sessions. The rally higher has been on much lighter volume and this is certainly a...
-
Morgan Stanley Maintains Overweight on Abbott Laboratories (ABT)
Wednesday, March 30, 2011 - 9:22am | 130Morgan Stanley is out with its report today on Abbott Laboratories (NYSE: ABT), maintaining Overweight. In a note to clients, Morgan Stanley writes, "Our 12-month price target for ABT is $55. Our price target is based on 11x Base Case 2012e EPS of $5.06. This represents a blend of valuation...
-
Gabelli Reports On VRX Offer For Cephalon
Wednesday, March 30, 2011 - 9:19am | 78Gabelli has issued a report on Valeant Pharmaceuticals' (NYSE: VRX) offer to acquire Cephalon for $73 a share, $5.7 billion total. According to Gabelli, “Valeant Pharmaceuticals (NYSE: VRX) is offering $73 per share for Cephalon ($5.7 billion in total) – call at 8:30am… Cephalon has a strong...
-
Piper Jaffray Reiterates Neutral Rating, $58 PT On CEPH
Wednesday, March 30, 2011 - 9:11am | 169Piper Jaffray is reiterating its Neutral rating and $58 PT on shares of Cephalon Inc. (NASDAQ: CEPH). “Last night, Valeant announced that it is making an unsolicited offer to acquire Cephalon for $73 per share in an all-cash transaction that values the company at $5.7B,” Piper Jaffray writes. “We...
-
Spectrum Pharma Continues Study of Lymphoma (SPPI)
Wednesday, March 30, 2011 - 9:01am | 35The Data Monitoring Committee has allowed Spectrum Pharmaceuticals (NASDAQ: SPPI) to continue the study for belinostat in peripheral T-cell lymphoma, after the Committee performed a safety analysis.
-
Lazard Upgrades XenoPort To Hold
Wednesday, March 30, 2011 - 8:56am | 20Lazard Capital Markets has upgraded XenoPort (NASDAQ: XNPT) from Sell to Hold.
-
Oppenheimer Initiates Coverage Of LCI With Outperform
Wednesday, March 30, 2011 - 8:53am | 113Oppenheimer has initiated coverage of Lannett Company Inc (AMEX: LCI) with an Outperform Rating. According to Oppenheimer, "We are initiating coverage of Lannett Company, Inc. (LCI) with an Outperform rating and a 12-18-month price target of $7. We believe the potential approval of LCI's morphine...